The global Preimplantation Genetic Testing Market is expanding as advances in reproductive medicine and genetic diagnostics increase the demand for embryo screening during in vitro fertilization (IVF). This growth is driven by increasing awareness of genetic health, improvements in fertility treatments, and the growing adoption of advanced diagnostic technologies in reproductive healthcare.

This growth reflects increasing awareness of inherited genetic disorders, rising utilization of assisted reproductive technologies, and continued improvements in genetic testing methods. Preimplantation genetic testing (PGT) enables clinicians to assess embryos for selected genetic or chromosomal abnormalities before an embryo is transferred to the uterus during IVF treatment. It can help identify embryos affected by specific inherited conditions and provide information to support reproductive decision-making.

Key market figures reported by Grand View Research include:

• Market size in 2025: USD 927.0 million

• Estimated market size in 2026: USD 1,007.8 million

• Projected market size by 2033: USD 2,368.4 million

• Forecast CAGR: 13.0% from 2026 to 2033

• Leading end-use segment: Hospitals, with a 38.9% revenue share in 2025

• Leading regional market: Europe, with a 40.7% revenue share in 2025

• Fastest-growing regional market: Asia Pacific, with a projected CAGR of 14.1% over the forecast period. 

Download a free sample copy of the Preimplantation Genetic Testing Market report to understand detailed coverage and inclusions in the final report

Key Growth Drivers 

1. Increasing adoption of in vitro fertilization

The growing use of IVF is a major factor supporting demand for preimplantation genetic testing. Individuals and couples experiencing infertility increasingly seek assisted reproductive technologies to help achieve pregnancy. As part of selected IVF treatment plans, PGT can provide genetic information about embryos before transfer.

The demand for PGT is also influenced by advanced maternal age, recurrent pregnancy loss, and family histories of inherited genetic disorders. In clinically appropriate cases, testing can help identify embryos with specific genetic abnormalities and support informed treatment decisions.

2. Rising awareness of inherited genetic disorders

Greater awareness of hereditary conditions is encouraging some prospective parents to consider genetic testing during fertility treatment. PGT for monogenic disorders can help identify embryos carrying specific genetic variants associated with inherited diseases, while testing for chromosomal abnormalities addresses different genetic risks.

Genetic counseling plays an important role in helping patients understand testing options, limitations, and possible outcomes. As access to reproductive genetics services expands, demand for specialized diagnostic testing is expected to increase.

3. Advancements in genomic technologies

Technological progress is improving the range of genetic information that laboratories can obtain from embryo samples. PCR-based methods are useful for detecting selected genetic variants, while NGS enables the analysis of multiple genetic targets and chromosomal information within a single testing workflow.

Laboratory automation, bioinformatics, and improved sample preparation are also helping testing providers streamline laboratory processes. These developments may improve operational efficiency and expand the capabilities of reproductive genetic testing.

Non-invasive approaches that analyze cell-free DNA in embryo culture media are also being investigated. Although promising, these methods require appropriate validation and should not automatically be considered equivalent to established biopsy-based testing.

Preimplantation Genetic Testing Market Segmentation

Procedure Insights

The preimplantation genetic diagnosis segment accounted for the largest share, representing 76.9% of market revenue in 2025. This segment focuses on identifying specific inherited genetic disorders or selected chromosomal rearrangements in embryos when a known genetic risk exists.

Demand is supported by growing awareness of inherited diseases, improved molecular diagnostic methods, and the availability of specialized reproductive genetics services.

Preimplantation genetic screening, commonly associated with PGT for aneuploidy (PGT-A), focuses on assessing chromosome number or selected chromosomal abnormalities. Its use and clinical benefits depend on patient characteristics and treatment objectives.

Product Insights

Reagents and consumables held the largest product share, accounting for 48.8% of market revenue in 2025. These products include testing kits, enzymes, amplification reagents, sequencing consumables, probes, and laboratory materials required for genetic analysis.

Their recurring use during laboratory procedures supports ongoing demand from fertility centers and diagnostic laboratories. As testing volumes and the range of available genetic assays expand, manufacturers have opportunities to develop more efficient and specialized consumables.

Instruments and software also contribute to the market. Instruments support sample preparation, DNA amplification, sequencing, and laboratory analysis, while software helps laboratories interpret genetic data, manage workflows, and generate reports.

Technology Insights

PCR dominated the technology segment with a 39.8% revenue share in 2025. Its established use, ability to amplify specific DNA sequences, and suitability for detecting selected genetic variants support its continued role in reproductive genetic testing.

NGS is another important technology, offering broad analysis of genetic material and chromosome-level information. Its ability to examine multiple targets in parallel makes it valuable for various PGT applications. Improvements in sequencing platforms and bioinformatics may further support adoption during the forecast period.

Fluorescent in-situ hybridization (FISH) and other genetic analysis methods also form part of the technology landscape, depending on the testing application and laboratory requirements.

Application Insights

Aneuploidy screening accounted for 26.2% of market revenue in 2025. This application evaluates embryos for abnormalities in chromosome number and is used in selected IVF treatment settings.

Other applications include testing for chromosomal abnormalities, X-linked diseases, embryo testing, human leukocyte antigen (HLA) typing, and other genetic conditions. These applications address different clinical needs, ranging from identifying inherited disorders to supporting selected embryo-matching decisions.

Go Deeper! Ask Prism AI

about the Global Preimplantation Genetic Testing Market. Get instant answers to

questions related to market sizing, growth drivers & their impact, and more.

Regional Outlook

Europe

Europe held the largest regional share, accounting for 40.7% of market revenue in 2025. Its position is supported by established reproductive healthcare infrastructure, specialized fertility clinics, and the availability of genetic diagnostic services.

Demand also reflects the utilization of IVF and the availability of advanced reproductive technologies. National regulations governing embryo testing and reproductive medicine differ across European countries, influencing which procedures are available and how they are performed.

Asia Pacific

Asia Pacific is projected to be the fastest-growing regional market, with a CAGR of 14.1% from 2026 to 2033. 

China, Japan, India, and other regional markets present opportunities for fertility clinics, diagnostic laboratories, and technology suppliers. Continued investment in laboratory capabilities and specialized reproductive medicine services may further support market development.

North America

North America is an important market for PGT, supported by advanced reproductive healthcare facilities, established diagnostic companies, and the availability of genomic testing technologies.

Demand is influenced by awareness of hereditary conditions, access to IVF, and interest in personalized reproductive care. However, treatment costs, insurance coverage, and regulatory considerations can affect access to testing.

Competitive Landscape and Key Companies

The preimplantation genetic testing market includes diagnostic laboratories, reproductive health specialists, genomic technology providers, and manufacturers of laboratory products. Key companies profiled by Grand View Research include:

• Quest Diagnostics Incorporated

• Natera, Inc.

• CooperSurgical, Inc.

• Genea Pty Limited

• Invitae Corporation

• Laboratory Corporation of America Holdings

• Thermo Fisher Scientific Inc.

• Bioarray S.L.

• Illumina, Inc.

• Igenomix

• F. Hoffmann-La Roche Ltd. 

Market participants focus on improving testing workflows, developing advanced genetic analysis technologies, expanding laboratory capabilities, and building relationships with fertility clinics. Innovation in sequencing, bioinformatics, and sample preparation is likely to remain an important area of competition.

Looking for more specific insights? Customize this report to suite your business needs